Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value (QNCX)

CUSIP: 22053A107

Q4 2024 13F Holders as of 31 Dec 2024

Type / Class
Equity / Common Stock, par value $0.0001 par value
Shares outstanding
55,541,178
Total 13F shares
5,108,991
Share change
-84,973
Total reported value
$9,553,550
Put/Call ratio
0.47%
Price per share
$1.87
Number of holders
34
Value change
+$495,078
Number of buys
18
Number of sells
12

Quarterly Holders Quick Answers

What is CUSIP 22053A107?
CUSIP 22053A107 identifies QNCX - Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value (QNCX) as of Q4 2024

As of 31 Dec 2024, Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value (QNCX) was held by 34 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 5,108,991 shares. The largest 10 holders included VANGUARD GROUP INC, EPIQ Capital Group, LLC, RENAISSANCE TECHNOLOGIES LLC, BlackRock, Inc., GEODE CAPITAL MANAGEMENT, LLC, HighTower Advisors, LLC, Shay Capital LLC, Alphabet Inc., ADAR1 Capital Management, LLC, and STATE STREET CORP. This page lists 34 institutional shareholders reporting positions in this security for the Q4 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.